NemaLife receives funding to develop a neurotherapeutic discovery platform
NemaLife receives funding to develop a neurotherapeutic discovery platform using next-generation psychedelic compounds. LUBBOCK, TX, USA,...
top of page
- Sep 20, 2022
NemaLife has received a Rising Star Award from BioNTX
2022 Rising Stars Announced at BioNTX’s iC³ Life Science Summit Rising Star Award Every year BioNTX selects Rising Stars in the life...
- Sep 13, 2022
NemaLife CTO receives the prestigious REDI award from the National Institute on Aging
NemaLife’s AI-assisted microfluidics-based tech platform receives funding to pursue rapid discovery of drug candidates that could improve...
- Jul 12, 2022
BioSpace Article - Worms: They’re a Lot Like Us, and that’s Good for Drug Development
To most, roundworms, or C. elegans, are just that: microscopic worms that live beneath our feet in the soil. But to scientists and...
- Jul 7, 2022
Collaborative effort led by Marian Walhout spotlights worms as model for personalized medicine
Multidisciplinary collaboration develops C. elegans as a model for investigating metabolism variations between individuals Marian...
- Jun 13, 2022
Google Interviews the NemaLife Team
Worms in the Cloud: How nematodes and AI are transforming R&D NemaLife is using AI and Cloud to drive faster, lower cost...
- Jun 9, 2022
US House passes legislation to end FDA animal testing mandate
FDA Modernization Act rider will spare animals, drive down drug prices and produce safer treatments and cures By EP News Bureau on June...
- May 4, 2022
Motif FoodWorks Announces Strategic Investment in NemaLife, Inc.
The collaboration will support Motif's rapid food-technology product pipeline by utilizing in vivo testing for functional properties of...
- Apr 19, 2022
DEA registered NemaLife Inc. to work with Schedule 1 substances
NemaLife Inc., completed its DEA schedule 1 registration. If you have scheduled compounds (schedule 1-5) to test, reach out to our...
bottom of page